Comparison of zanubrutinib (zanu) and acalabrutinib (acala) in B-cell malignancies: An adverse event (AE)-based analysis

Authors
Category Systematic review
JournalJ. Clin. Oncol.
Year 2024
This article has no abstract
Epistemonikos ID: 204165071e9a22eeaa3930d11665e5ea3bcb7ac9
First added on: Aug 14, 2024